Did you know that genital herpes, caused by the herpes simplex virus type 2 (HSV2), is a common and recurrent viral infection affecting millions worldwide? Living with genital herpes can be challenging, not only due to physical symptoms but also due to the emotional and psychological impact. However, a groundbreaking opportunity is on the horizon – and you can be a part of it.
Current treatments for genital herpes can help manage symptoms and reduce the risk of transmission, but they cannot completely prevent outbreaks or viral shedding. This study explores the potential of a novel mRNA vaccine to change this narrative, offering hope for a more effective management approach.
Our goal is simple yet profound: to evaluate the effectiveness of the mrna-1608-p101 vaccine in reducing the frequency and severity of genital herpes outbreaks, as well as decreasing viral shedding. By achieving this, we could significantly improve the quality of life for those living with HSV2.
We are eager to make a difference, but we need your assistance. If you or a loved one has been diagnosed with genital herpes and meets our eligibility criteria, consider referring them to our study.
Introducing our Phase 3 clinical trial, Study RNLC3132, an endeavor designed to delay the onset of OHE in liver cirrhosis patients. This randomized, double-blind, placebo-controlled study aims to explore the safety and effectiveness of a promising treatment, Rifaximin SSD-40mg. Our goal isn’t just to mitigate the disease but to enhance the quality of life for those living with cirrhosis.
We are eager to make a difference, but we need your assistance. If you or a loved one has been diagnosed with liver cirrhosis and meets our eligibility criteria, consider participating in this pivotal study.